Corporate News

Further positive data for Mologic COVID-19 lateral flow antigen test

05 May 2021

Mologic test shows high diagnostic accuracy (specificity and sensitivity)

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the Mologic COVID-19 lateral flow antigen test has been independently verified in a 665-person study in Germany by FIND a global not-for-profit foundation. The test was shown to demonstrate best-in-class performance with 100% specificity and 96.4% sensitivity (Cycle threshold <25) compared with laboratory PCR testing.

FIND (, is a World Health Organization collaborating centre for laboratory strengthening and diagnostic technology evaluation and seeks to find diagnostic solutions to overcome diseases of poverty in lower- and middleincome countries. 

The report is available to read here: 

Omega has CE-Marked the Mologic lateral flow antigen test for COVID-19 and has launched the test for professionaluse under Omega’s VISITECT® brand. The VISITECT® COVID-19 Antigen test provides healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs in 10 minutes.   

For further information please visit: VISITECT® COVID-19 Antigen Test | Omega Diagnostics 

Colin King, CEO of Omega, commented: “This is great news for the Mologic test, which we are now producing under our VISITECT brand. It is significant that the test has been shown to have high diagnostic accuracy on self-collected swab specimens. Rapid diagnostic tests play a crucial role in breaking the spread of infection in the community and we are delighted to be a leading manufacturer of these home-grown tests.”




Omega Diagnostics Group PLCTel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director  
finnCap LtdTel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)  
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

Sign up for Investor Alerts